How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,272 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Changes in pupil size and intraocular pressure after topical application of 0.5% tropicamide to the eyes of dogs sedated with butorphanol. (Abstract)

) or an equal volume of sterile saline (0.9% NaCl) solution. For each dog, 1 drop of 0.5% tropicamide ophthalmic solution was topically instilled in one eye and 1 drop of artificial tear solution was topically instilled in the other eye 10 minutes after the IM injection and again 5 minutes later. Extent of sedation, pupil size, and IOP were evaluated from 20 minutes before to 80 minutes after the IM injection and compared among treatment combinations.Butorphanol induced mild (n = 9) or moderate (3) sedation (...) Changes in pupil size and intraocular pressure after topical application of 0.5% tropicamide to the eyes of dogs sedated with butorphanol. To assess changes in pupil size and intraocular pressure (IOP) following topical application of a 0.5% tropicamide solution in the eyes of healthy butorphanol-sedated dogs.12 healthy adult Beagles.In a randomized crossover study consisting of 2 treatment periods with a 1-week washout between periods, dogs received an IM injection of butorphanol (0.2 mg/kg

2019 American journal of veterinary research

102. Tear lipid supplement prophylaxis against dry eye in adverse environments. (Abstract)

containing drop (Systane® Ultra) applied simultaneously to the contralateral eye. Subjects were subsequently exposed to a validated simulated adverse environment model created by a standing fan directed towards the eye, at a distance of 1m, for 2.5min. Low contrast glare acuity, lipid layer grade (LLG), non-invasive tear break-up time (NIBUT), temperature variation factor (TVF), and tear meniscus height (TMH) were evaluated at baseline, following eye drop instillation and following simulated adverse (...) Tear lipid supplement prophylaxis against dry eye in adverse environments. To compare the prophylactic efficacy of single application of lipid and non-lipid containing tear supplements, prior to exposure of symptomatic dry eye subjects to a simulated adverse environment.Thirty subjects with mild-to-moderate dry eye symptoms participated in the prospective, randomised, double-masked, paired-eye trial. A lipomimetic drop (Systane® Balance) was applied to one eye (randomised), and a non-lipid

2019 Contact lens & anterior eye : the journal of the British Contact Lens Association Controlled trial quality: uncertain

103. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. (Full text)

in China. Our study aims to compare the efficacy and safety profile of 0.05% CsA OE versus vehicle in Chinese patients with moderate to severe DED.This was a multicenter, randomized, double-masked, 2-parallel-arm, 3-month phase III study. Patients with moderate to severe DED were randomized to receive twice-daily 0.05% CsA OE or its vehicle, along with unpreserved hypromellose eye drops 3 times per day. Patients were followed up at day 7, 28, 56, and 84, as well as 2 weeks after the medications were (...) Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. Dry eye disease (DED) is a chronic ocular surface disease that affects hundreds of millions of people worldwide. Although 0.05% cyclosporine ophthalmic emulsion (CsA OE) has long been prescribed in the U.S. for the treatment of DED, it is not commercially available

2019 Medicine Controlled trial quality: uncertain PubMed abstract

104. Abusive Head Trauma and the Eye in Infancy

Abusive Head Trauma and the Eye in Infancy 1 The Royal College of Paediatrics and Child Health and The Royal College of Ophthalmologists Abusive Head Trauma and the Eye in Infancy June 2013 Scientific Department The Royal College of Ophthalmologists 17 Cornwall Terrace Regent’s Park London NW1 4QW Telephone: 020 7935 0702 Facsimile: 020 7487 4674 www.rcophth.ac.uk © The Royal College of Ophthalmologists 2013 All rights reserved For permission to reproduce any of the content contained herein (...) baby syndrome 35. SIGN Scottish intercollegiate guidelines network 36. SDH Subdural haemorrhage 7 Guideline Working Party (GWP) Chairman Patrick Watts, Consultant Ophthalmologist, Cardiff, Wales Working Party Gillian Adams Consultant Ophthalmologist, Moorfields Eye Hospital London John Ainsworth Consultant Ophthalmologist, Children’s Hospital, Birmingham Susmito Biswas Consultant Ophthalmologist, Children’s Hospital, Manchester Richard Bonshek Consultant Pathologist, Manchester Royal Eye Hospital

2013 Royal College of Ophthalmologists

105. Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. (Full text)

upon antioxidant/essential polyunsaturated fatty acid supplementation. Chronic instillation of antihypertensive eye drops must be considered for integrating protocols to glaucoma standards of care. (...) Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Glaucoma and dry eye disorders (DEDs) are frequent comorbidities. The antioxidant and anti-inflammatory properties of essential polyunsaturated fatty acids have been extensively studied in relation to eye diseases.Our objective was to determine the effects of oral supplementation

2013 Clinical interventions in aging Controlled trial quality: uncertain PubMed abstract

106. Effect of nepafenac eye drops on intraocular pressure - a randomized prospective study. (Abstract)

was randomized to the treatment group, with the other eye acting as a control. Nepafenac (0.1%) eye drops were instilled 3 times a day in the eye that received treatment. Intraocular pressure (IOP) with Goldmann applanation tonometer (GAT) was measured at baseline and at 4 and 8 weeks. Proportion of eyes with an IOP elevation of >4 mm Hg was the main outcome measure.The mean age of the participants was 45.7 ± 4.4 years. Participants included 192 female and 135 male patients. The mean IOP at baseline (...) Effect of nepafenac eye drops on intraocular pressure - a randomized prospective study. To report the effect of nepafenac (0.1%) eye drops on intraocular pressure in eyes with cataract.Prospective randomized clinical trial.Three hundred and twenty-seven patients with bilateral cataracts in an institutional setting were included. All patients had a baseline intraocular pressure (IOP) ≤ 21 mm Hg without a history of intraocular surgery in the past 3 months. One eye of each individual

2013 American Journal of Ophthalmology Controlled trial quality: uncertain

107. Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects

administered Olixia pure® eye drops on tear film thickness in healthy subjects. Tear film thickness will be determined using ultra high-resolution optical coherence tomography (OCT). Measurements will be performed before instillation of the eye drops and every 10 minutes after instillation for one hour. One eye will receive Olixia pure® eye drops, the fellow eye will receive physiologic saline solution as placebo control. The study eye will be chosen randomly. Condition or disease Intervention/treatment (...) Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2013 Clinical Trials

108. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. (Abstract)

. At baseline and 12 weeks, patients demonstrated drop instillation using a bottle of artificial tears.Patient self-assessment of difficulty with drop administration and observed patient difficulty with drop administration, defined as bottle touching eye/adnexa, drop missing the ocular surface, or administering more than 1 drop.Of 164 enrolled patients, 50% had previously been treated with ocular hypotensive medication for ≥3 years. Only 11.4% of patients reported difficulty with eye drop administration (...) at study entry. At baseline, 18.2% of patients touched their eye/adnexa with the bottle and 10.3% missed the eye. At 12 weeks, 18.5% and 8.6% of patients, respectively, had similar difficulties. Overall, difficulty with drop instillation was observed in 42.1% of patients. Difficulty at both visits was seen in 35.3% of patients who reported difficulty at entry and in 17.2% of patients who denied difficulty. The relative risk of demonstrating difficulty at either visit was 2.0 times greater for patients

2013 Current medical research and opinion

109. Dry eye syndrome

made. June 2012 — minor update. Typographical error corrected. March 2011 — technical update. The management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations. September 2010 — minor update. Hydromoor® (hypromellose 0.3% preservative-free single dose eye drops) have been included. Issued in September 2010. March 2010 — minor update. Lubri-Tears® eye ointment has been discontinued (...) . Prescription removed. Issued in March 2010. December 2007 to March 2008 — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Although there is a new section on assessment, there are no major changes to the recommendations. January 2006 — minor update. Black triangle removed from carmellose sodium eye drops. Issued in February 2006. September 2004 — reviewed

2017 NICE Clinical Knowledge Summaries

110. Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose (Full text)

).This was a double-masked, randomized, parallel-group study conducted in 14 clinical centers in Canada and Australia. Subjects with no more than mild dry eye instilled CMC-HA or CMC for 90 days post-LASIK. Ocular Surface Disease Index© (OSDI; primary efficacy measure), corneal staining, tear break-up time (TBUT), Schirmer's test, acceptability/tolerability surveys, and visual acuity were assessed at screening and days 2, 10, 30, 60, and 90 post-surgery. Safety analyses included all enrolled.A total of 148 (...) , reaching statistical significance at day 30 (P=0.013). Both treatments were well tolerated.CMC-HA-containing artificial tears relieved post-LASIK ocular dryness as well as CMC alone, and demonstrated incremental benefit in uncorrected vision, with a favorable safety profile. Results support use of CMC-HA eye drops to reduce signs and symptoms of ocular dryness post-LASIK.

2018 Clinical ophthalmology (Auckland, N.Z.) Controlled trial quality: uncertain PubMed abstract

111. Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery

tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks. Active Comparator: Preservative containing diquafosol group The subjects (...) solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks. Active Comparator: Preservative free sodium hyaluronate group The subjects use preservative

2018 Clinical Trials

112. Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

will then be determined. All pre-treatment assessments will be done at this visit. Randomization will occur. If randomized to receive Xiidra eye drops, a prescription will be written and the treatment will be started right away. If randomized to eyelash prostheses, then a second study visit will be made approximately 2 weeks later. Visit 2 (Eyelash Prostheses application) Subjects randomized to receive eyelash prostheses will have them applied approximately 2 weeks after the screening and randomization visit. Visit 3 (...) (Final visit) will be 3 weeks post eyelash prosthesis placement and 5 weeks post Xiidra eye drop initiation. This was done to compare the maximal treatment effect between the two groups. All subjects will undergo post-treatment assessments. At each visit, patients will be asked to report any adverse events. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Allocation: Randomized Intervention Model: Parallel

2018 Clinical Trials

113. Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease (Full text)

decreased, and tear breakup time (BUT) increased for both groups (p < 0.001 each). Mean instillation frequency was 3.1 ± 2.6 drops/day when using HT and 1.9 ± 2.2 drops/day when using HTC-gel (p=0.02). A significant improvement in the quality of sleep was observed with both treatments (p=0.01).Our results show improvement in signs and symptoms of DED in both groups. While instillation of HTC-gel resulted in a lower instillation frequency, both formulations of trehalose showed good clinical efficacy (...) Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease This randomized, observer-masked, crossover study investigated the effect of two hyaluronic acid/trehalose-based containing formulations, with different physical properties, on the signs and symptoms in patients with moderate to severe dry eye disease (DED).In one group, patients received a mixture of sodium hyaluronate and trehalose (HT, Thealoz Duo®

2018 Journal of ophthalmology Controlled trial quality: uncertain PubMed abstract

114. Flicker electroretinograms of eyes with cataract recorded with RETeval system before and after mydriasis (Full text)

Flicker electroretinograms of eyes with cataract recorded with RETeval system before and after mydriasis The aim of this study is to determine the effect of pupil size of eyes with cataracts on the flicker electroretinograms (ERGs) elicited and recorded with the RETeval system.Forty-one eyes of 41 patients (mean age, 76.5±7.3 years) that had grade 2 nuclear or cortical cataract without any other abnormalities were studied. Flicker ERGs were recorded before and after mydriatic drops instillation (...) ). The mean amplitudes and implicit times of the nuclear and cortical cataracts groups before the mydriasis were also not significantly different from those after mydriasis for all stimulus intensities.The lack of significant differences in the amplitudes and the implicit times of the flicker ERG of cataractous eyes before and after mydriasis indicated that the RETeval flicker ERGs in cataractous eyes is less affected by the pupil diameter. With our earlier study, it was assumed that the effect

2018 Clinical ophthalmology (Auckland, N.Z.) PubMed abstract

115. Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency (Full text)

% or 0.3% sodium hyaluronate (SH) eye drops by using the LipiView ocular surface interferometer.In the lipid deficiency group, the LLT increased from baseline at 1min post instillation. The LLT after the instillation of 0.1% SH was significantly higher than that after the instillation of 0.3% SH (P<0.001). The LLT returned to baseline at 15min post instillation of 0.1% SH and at 5min post instillation of 0.3% SH. In the non-lipid deficiency group, the LLT decreased from baseline at 1min and returned (...) Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency To investigate the effects of different concentrations of artificial tears on lipid layer thickness (LLT) and blink rate (BR) in dry eye patients.This study included 106 eyes of 58 patients with dry eye. The lipid deficiency type was defined as the LLT baseline <75 nm. The LLT and BR were measured at baseline and 1, 5 and 15min after the instillation of 0.1

2018 International journal of ophthalmology PubMed abstract

116. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction (Full text)

Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD).In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free (...) sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia

2018 International journal of ophthalmology Controlled trial quality: uncertain PubMed abstract

117. Immediate effect of a tear enhancer and meibomian gland expression on the corneal surface and whole eye higher order aberrations (Full text)

subjects (25 females, mean age±sd 32.5±11.0 years, and 25 males, 33.88±11.2 years) for two pupil sizes (3 and 6mm) in a dark environment. One drop of Blink Contacts™ (Abbott Medical Optics) was instilled into the right eye and HOA measurements repeated after 30s. After 1h, the meibomian glands of the left lower eyelid were gently squeezed and HOA measurements repeated after 30s.There was no significant difference for CS and WE root mean square (RMS) HOAs between right and left eyes before (both pupil (...) Immediate effect of a tear enhancer and meibomian gland expression on the corneal surface and whole eye higher order aberrations To investigate changes in higher order ocular aberrations (HOA) induced by the administration of 0.15% sodium hyaluronate tear enhancer (TE) and meibomian gland expression (ME) on the tear film of normal subjects.HOA values were obtained from the corneal surface (CS) and whole eye (WE), using a corneal topographer and Shack-Hartmann aberrometer, from both eyes of 50

2018 Journal of optometry PubMed abstract

118. Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

: Voclosporin Ophthalmic Solution Investigational Drug Other Name: 0.2% VOS Active Comparator: Comparator 0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days Drug: Restasis® Comparator Other Name: RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% Outcome Measures Go to Primary Outcome Measures : Drop Discomfort Assessment Visual Analogue Scale(VAS) [ Time Frame: 1-minute Post-Dose 1 instillation ] VAS scale 0 - 100 - Where 0 is the no discomfort and 100 the worst discomfort (...) excipients), topical anesthetics or vital dyes. Be unable to demonstrate correct instillation of over-the-counter (OTC) ocular lubricant. Report discomfort in both eyes from instillation of OTC ocular lubricant during Visit 2 (based on score of ≥30 on the Drop Discomfort VAS). Have used Restasis® (cyclosporine ophthalmic emulsion) within 30 days prior to Visit 1. Have used Restasis® for more than 1 month (if prior use is reported). Have used Xiidra® (lifitegrast ophthalmic solution) within 14 days prior

2018 Clinical Trials

119. REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

and Interventions Go to Arm Intervention/treatment Experimental: Remogen Device: Remogen instil 1 drop of the product in each eye, 4 times per day Active Comparator: Cationorm Device: Cationorm instil 1 drop of the product in each eye, 4 times per day Outcome Measures Go to Primary Outcome Measures : OSSF [ Time Frame: Day 28 ] Ocular surface staining with fluorescein (OSSF) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

120. Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

Experimental: Treatment lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day Drug: Lifitegrast Eye drop Other Name: Xiidra Outcome Measures Go to Primary Outcome Measures : Number of hours related to comfort in wearing contact lenses. [ Time Frame: Baseline to Week 12. ] The amount of comfortable lens wear time averaged over the 12th week of lens wear as reported with participant diary. Secondary Outcome Measures : Number of hours related to comfort in wearing contact (...) , the investigators may be able to relieve some of that discomfort. This study will enroll 50 subjects with contact lens discomfort and will receive lifitegrast to use over a period of approximately 3 months. Condition or disease Intervention/treatment Phase Contact Lens Dry Eye Drug: Lifitegrast Phase 4 Detailed Description: The most common reason for contact lens drop out is ocular discomfort, with patients identifying dryness as the major reason. Currently, many patients with contact lens dry eye (CLDE

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>